What's new at Anthogen.

JointFit, the newest module in the ARTA Health System, launches today with pre-operative conditioning and post-operative recovery tracks for knee and hip replacement.

The module was co-developed with a panel of orthopedic surgeons and physical therapists, and includes computer-vision-guided range-of-motion checks, daily pain and swelling capture, and adaptive home-exercise progression.

JointFit shares the same ARTA infrastructure as CardiFit — a single clinician dashboard, the same adherence engine, and the same direct-to-patient delivery model — making it straightforward for existing health-system partners to add the program alongside their cardiac service line.

Twelve-month outcome data from the first four health systems to deploy CardiFit has been accepted for publication in a peer-reviewed cardiac rehabilitation journal.

Across 412 patients enrolled in the at-home program, weekly session adherence reached 89% — compared with 63% historically reported for traditional in-clinic rehab in matched populations. Thirty-day cardiac readmissions in the cohort were 62% lower than the health systems' baselines.

The paper attributes the result to three factors: removing the transportation and scheduling barriers of in-clinic visits, the adaptive coaching engine that personalizes intensity day to day, and the always-available chat with a real care coach during the critical first eight weeks of recovery.

Anthogen has closed its Series A financing, led by a strategic healthcare-focused fund with participation from existing investors. Proceeds will fund expansion of the ARTA module library, additional clinical evidence generation, and the build-out of the U.S. commercial team.

The round closes a year that saw CardiFit deployment quadruple and the FDA accept the company's pre-submission for the next ARTA module.

"Series A lets us move from proof to scale," said Daniel Nadis, CEO of Anthogen. "The clinical evidence is in; the demand from health systems is in. Our job now is to make sure every patient who needs an ARTA program can get one."

The FDA has accepted Anthogen's Pre-Submission for the next ARTA module, confirming the regulatory pathway for a condition-specific program currently in late-stage internal development.

Pre-Sub feedback aligned with Anthogen's planned study design and predicate-device approach, and the company expects to begin its pivotal study in the first half of next year.

Anthogen's regulatory strategy across all ARTA modules emphasizes real-world evidence collected continuously from the at-home program, complementing traditional clinical-trial data.

Anthogen has been named to the annual Digital Health 50 list, recognizing the fifty private digital-health companies most likely to shape the next decade of care delivery.

Analysts cited Anthogen's clinical evidence, the at-home adherence outcomes reported by CardiFit partner sites, and the modular ARTA platform that lets new condition programs launch without rebuilding patient-facing infrastructure.